Osteoblast expression of cytokines is altered on MTA surfaces.
OBJECTIVE
Mineral trioxide aggregate (MTA) is used within areas of periradicular inflammation. Therefore, the purpose of this study was to determine if osteoblasts that attach to MTA surfaces alter their expression of inflammatory cytokines.


METHODS
Mouse MC3T3-E1 preosteoblasts were seeded onto ProRoot (Pr-MTA) and Tooth-Colored (Tc-MTA) MTA surfaces, as well as commercially pure titanium (cpTi) and tissue culture plastic (TCP) controls. Cell-surface interactions were visualized by inverted fluorescence microscopy. After 24 hours of attachment, the cells were stimulated with bacterial lipopolysaccharide (LPS) and analyzed by reverse-transcription polymerase chain reaction.


RESULTS
Numerous cells attached and spread out onto Pr-MTA and Tc-MTA, as they did on cpTi and TCP. They formed plentiful extensions and a spindle-shaped morphology on the granular MTA surfaces. Cells grown on TCP and cpTi expressed an abundance of interleukin (IL-6) and IL-1alpha upon LPS exposure. Cells on Pr-MTA and Tc-MTA produced IL-6 but failed to express IL-1alpha despite LPS stimulation.


CONCLUSIONS
Osteoblast expression of inflammatory cytokines is altered on endodontic MTA surfaces compared with titanium implants and plastic controls.
Deller-Quinn
Miranda
M
Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Perinpanayagam
Hiran
H
D017607:Aluminum Compounds / Q000494:pharmacology*; D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology; D017610:Calcium Compounds / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects*; D002460:Cell Line; D003738:Dental Cements / Q000494:pharmacology*; D004338:Drug Combinations; D007378:Interleukins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D010087:Oxides / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D012387:Root Canal Filling Materials / Q000494:pharmacology; D017640:Silicates / Q000494:pharmacology*; D014025:Titanium / Q000494:pharmacology
D017607:Aluminum Compounds; D001672:Biocompatible Materials; D017610:Calcium Compounds; D003738:Dental Cements; D004338:Drug Combinations; D007378:Interleukins; D010087:Oxides; D012333:RNA, Messenger; D012387:Root Canal Filling Materials; D017640:Silicates; C086631:mineral trioxide aggregate; D014025:Titanium